A study showed the sex differences in serum proteomic profiles of males and females with PsA. Key findings: -Identified 741 unique proteins in male PsA patients vs. controls vs. 31 in females. - Several sex-specific pathways, including immune cell functions and cytokine… https://t.co/erC599Zbuj

• https://x.com/i/web/status/1858250004697391431

A#1746 companion for RA Like plenary for PsA, PBO response incr w time 1%/yr More trials in less affluent countries may be related to increasing PBO response in trials Possible reason: access to health care improves PBO in less affluent areas @RheumNow #ACR24 https://t.co/S3LffF8vPH

• https://twitter.com/ericdeinmd/status/1857803974922903912

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52. Supports addtl evidence of BKZ's winning streak in #axSpA @RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8

• https://x.com/RHEUMarampa/status/1858231890827706410/photo/1

A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA. @RheumNow https://t.co/ospR0qEIsd

• Apremilast Benefits and Risks in PsA | RheumNow

Smoking and Rx progression in PsA? -Prospective Canadian cohort of 1736 PsA pts. -Older age, BL SJC, dactylitis, erosions and high ESR were associated with Rx progression. 🚨Cigarette smoking did not appear to be associated with the Rx progression in PsA. Abst#1436 #ACR24… https://t.co/J2IogqOlx8 https://t.co/U6SRmbOE6o

• https://x.com/i/web/status/1858208485722255551
• https://x.com/AdelaCastro222/status/1858208485722255551/photo/1

This study by Dr. UGazel et al shows that cervical DISH in SpA is similar to the general population. Of note, HLAB27+ axSpA pts had more DISH while PsA pts had DISH if they were HLaB27(-) @RheumNow #ACR24 abs1447 https://t.co/GtcvxVSb8B

• https://x.com/RHEUMarampa/status/1858199028069961871/photo/1

Gonzalez Molina et al. MANHATTAN observational study. In PsA after 1st TNFi failure should we use guselkumab or 2nd TNFi? Guselkumab slightly better persistence, DAPSA, and improvements in joint counts. @RheumNow #ACR24 Abstr#1469 https://t.co/X3TMCVys6B https://t.co/vvkUYbzVDq

• Manhattan Study: Observational, Ambispective Study to Describe Persistence and …
• https://x.com/RichardPAConway/status/1858194388360282291/photo/1

Kharouf et al. Secondary biologic failure in PsA common - 36% over 5 years. Predictors - higher baseline SJC HR 1.39 and PASI HR 1.14. TNFi did better, HR 0.40, esp golimumab - but ?this as often used as first bDMARD? @RheumNow #ACR24 Abstr#1455 https://t.co/ET0WX6tKMr https://t.co/iVcCkM0hu3

• Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients w…
• https://x.com/RichardPAConway/status/1858187341455573295/photo/1

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

• Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab vers…
• https://x.com/RichardPAConway/status/1858190864708780251/photo/1